SIRIO 30CPR EFF 25mg 100mg
Active MELEVODOPA hydrochloride / carbidopa therapy group HYDRATED
dopaminergic
Product Type Ethical Regime SSN CONCEDIB.ESENTE
Class A Recipe Type RR - Repeat
Form Farm. EFFERVESCENT CPR / Container SOLUBLE BLISTER
Commerc Data valid for 24 months. 07/10/2005 Price
ATC N04BA05
The product does not contain gluten Gluten
Manufacturer Chiesi Farmaceutici SpA
Pharmacotherapeutic
Melevodopa and decarboxylase inhibitor.
ACTIVE
should not be used during pregnancy, during pregnancy or suspected
during lactation. INDICATIONS
Therapy of Parkinson's disease. The treatment and 'market
particularly suitable for patients with motor fluctuations (akinesia on awakening, pom
eridiane, end of dose).
CONTRAINDICATIONS / EFF.SECONDAR
must not be used in cases in which 'som
contraindicated administration of sympathomimetic amines. E 'contraindicated with hypersensitivity pazie
nts' to the active substances or to any of
ccipienti and in narrow-angle glaucoma and in the acute phase of the infection
rto infarction. Since 'levodopa may' turn a Malig melanoma
not, should not be used in patients with suspicious skin lesions
not diagnosed or with a history of melanoma.
nonselective inhibitors of monoamine oxidase (except selective MAO-B inhibitors to ba
ssi doses) and should not be administered simultaneously and
therapy with these inhibitors should be discontinued at least two week
anesthetized before treatment with the drug. The product de ve
be administered in patients' less than 18 years,
during pregnancy and lactation.
DOSAGE
Association melevodopa and carbidopa, and 'in the form of c
ompresse effervescent. Each tablet contains 314 mg of the
melevodopa hydrochloride equivalent to 250 mg levodopa and 25 mg carbidopa anhydrous
(Sirius 25 mg +250 mg) or 157 mg of melevodopa
hydrochloride equivalent to 125 mg levodopa and 12.5 mg carbidopa anhydrous (12.5 mg +125 mg
Sirius) or 125.6 mg melevodopa hydrochloride 100 mg levodopa and 25 m
g of anhydrous carbidopa (Sirius 25 mg +100 mg). Conversion melevodopa-lev
odopa for equimolar ': melevodopa 314 mg levodopa = 250 mg; melevodo
pa 157 mg levodopa = 125 mg; melevodopa 125.6 mg = 100 mg levodopa. The
effervescent tablets are dissolved in 150 ml of water. The co
MPRESS effervescent than 3 doses available, can be administered
Istrate separately or jointly depending on the need 'to
achieving the optimum dosage, you get so', a specific modulation
ion doses. The dosage should be titrated according to the needs
'individual patient and what' can require an adjustment
ation of both the individual dose and frequency of administration
one. Some studies show that peripheral dopa decarboxylase is saturated by carbidopa
with a dose of approximately 70-100 mg / day. The pazie
nts who receive lower doses of carbidopa and 'more' likely to resent pre
nausea and vomiting. Patients should be monitored closely
during the titration. The onset of involuntary movim
institutions may 'require a dose reduction in some patients
; blepharospasm can' be a useful early sign of excessive dosage
Thurs. In the case of general anesthesia, can 'be continued
inche f' to the patient and 'allowed to take liquids and medicines by mouth
a. If therapy is interrupted temporarily, the usual dose
daily and can 'be used when the patient is able
or take oral medications. In patients that are not treated with levodopa treatment
more 'optimal starting dose of carbidopa S
Irio +100 mg and 25 mg' of an effervescent tablet three times daily
o. The dosage can 'be increased by one tablet
in the day, or every other day, as needed. The usual starting dose of Sirius
12.5 mg and 25 mg +125 mg +250 mg '
a tablet once or twice per day and increased, if necessary,
effervescent tablet a day or every other day until you get a
optimal response. In patients already 'treated with formulations
wings or solid (capsules or tablets) of levodopa more' carbidopa and when you replace
Pre-treatment with the effervescent tablets, the dosage unit
l / day will be 'exactly equivalent in terms
ni molars than previously administered. As with other formulations of levodopa + carbidopa
lations available in most paz
othing can 'be given a maximum dose of maintenance incl
examined between 3 and 6 effervescent tablets per day.
WARNINGS
Can 'be used to replace other forms of lev
odopa, in which case the dosage of melevodopa will' exactly fair
alent molar to the unit / day of levodopa pr
ecedentemente taken. Patients treated with the product nno
will have to avoid taking additional doses of levodopa, unless s ian
been prescribed by your doctor, while the other ant
iparkinsoniani drugs can be continued, although it may become neces sary
a dosage adjustment. It 's not recommended for the treatment of
drug-induced extrapyramidal reactions. Patients with psychosis in
act or to history should be treated with caution. As the levod
opa, can 'cause involuntary movements and mental disturbances. C
patients on a history of severe involuntary movements or psychotic episodes quand
or treated with other formulations of levodopa should be carefully observed
when you replace them drug.
All patients should be closely monitored for the development of modificazi
oni mental depression with suicidal tendencies or other serious antisocial behavior
treatment. Should be administered with caution to patients with severe cardiovascular disease or
lung, bronchial asthma, distu
RBI kidney, liver or endocrine. Caution should be exercised in somm
inistrare the drug to patients with a history of myocardial infarction p
Resentin residual atrial, nodal or ventricular arrhythmias. In such Pazi
institutions, cardiac function should be monitored with special att ention
during the initial dose adjustment. Com
and levodopa, there the possibility 'of tract hemorrhage gast
rointestinale more' pronounced in patients with a history of peptic peptide
ca. Strict warning even if
patients with a history of osteomalacia. When
antiparkinsonian medications were discontinued abruptly and 'complex has been reported
matologia symptoms similar to neuroleptic malignant syndrome with rigidity' Musc
Olare, elevated body temperature, mental changes and increased serum creatinine
. Therefore, patients should be monitored closely n the t
when the dosage is reduced or suspended brus
cally, especially if the patient is receiving neuroleptics. The patients
with a history of seizures should be treated with care when
canvas. There have been reports of the syndrome of pathological gambling azz
burn, increased libido and hypersexuality ',
ation in patients with dopamine agonists for Parkinson's disease, including
the drug. Levodopa, levodopa + carbidopa, levodopa + benserazide, and 'ta
is associated with somnolence and episodes of sudden sleep onset.
Very rarely have been reported sudden onset of sleep dur ante
activity 'daily, in some cases without awareness, and if
nza signs. Patients treated with levodopa + carbidopa to levodopa
, levodopa + benserazide should be informed of these ev
for printing 'and advised to use caution while driving or operating but
cchinari. Patients who have experienced somnolence and / ou
n episode of sudden sleep onset must refrain from driving and use
machines. Also it can 'be considered a reduction
one dose or discontinuation of therapy. In the case of the prolonged and trattament
'practice should be periodic examinations of blood count and functionality
ica' liver, kidney and cardiovascular system. The Pazzi
entities with chronic open-angle glaucoma can be treated with
the product, as long as' the intraocular pressure is well compensated and the patient is controlled
carefully during therapy. The doctors
tional lactose therefore patients with rare hereditary problems ered
ITAR of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption
should not take this med
icinale. Laboratory tests: with the administration of levodopa more
'carbidopa were observed alterations in laboratory test comp
making: increased SGOT, SGPT, LDH, bilirubin, alkaline phosphatase
, as well as' increases in nitrogen, creatinine
nina, uric acid and positivity 'Coombs. The hemolytic anemia
policy and 'extremely rare. Have been reported: decrease dell'emog
Lobina and hematocrit, increased serum glucose and blood cells b
Ianca and presence of bacteria in blood and urine.
INTERACTIONS
Care must be taken when the following drugs are administered in conjunction with the product you
. Antihypertensives: you can 'check ip
otensione postural system when it is' administered to a patient already
to' being treated with antihypertensive drugs. So when you start to
therapy with the drug, may 'be required
adjustment of the dosage of the antihypertensive drug. Antidepressants:
and inhibitors of monoamine oxidase-A and the product should not be given c
ontemporaneamente and treatment with these inhibitors should be planted at least two weeks
eet before treatment with the drug
co. Have been rarely reported adverse reactions, including
hypertension and dyskinesia, resulting from the use of concomitant tricyclic antidep
interests and levodopa. Other drugs: phenothiazines and butter
rofenoni may reduce the therapeutic effects of levodopa. Inolt
king, 'has been reported that the therapeutic effects of levodopa in Parkinson's disease
are reduced by phenytoin and papaverine. The
patients taking these drugs with the product must be att
entamente examined for possible reduction in the r
Replies to therapy. Since levodopa competes with certain amino acids
, its absorption can 'be compromised in some patients at el
EVAT protein diet. Vitamin B6 in medium or high doses should not be som
ministered with the product as it antagonizes the effects of levodopa
: this activity 'antagonist is not clinically relevant in
c aso of low-dose vitamin B6, such as those contained in some preparations
livitaminici.
SIDE EFFECTS
With the drug dosage normally used and not 'ta
observed in clinical trials the occurrence of serious adverse reactions
related to the administration of the drug. Reactions have been reported
tions adverse typically mild to moderate load apparatus
gastrointestinal (nausea and vomiting), nervous system (dizziness,
igidita r ', headache, and dyskinesia), psychiatric disorders (disorder and confusion onno
s) General disorders (fatigue ', syncope and chest intent
King) and less frequently in the cardiovascular system and
(fluctuations in blood pressure and arrhythmias). These reactions are generally not know
of short duration and are in most cases of
and resolved spontaneously. Side effects that may
r overagainst in patients treated with the product are due to the activity
ita 'central neuropharmacological dopamine, similar to those described for
levodopa + carbidopa formulations available. Ques
effects you usually can be decreased by reducing the dosage
. The most 'common are choreiform, dystonic and other involuntary movements of
.
muscle fibrillation and blepharospasm can be considered as warning signs to decide
a reduction in dosage. Since carbidopa increases the ion concentration
of levodopa to the brain, treatment with levodopa + carb
idopa can 'cause dyskinesia. Other side effects observed do
while taking levodopa were: mental disorders including ideaz
ion paranoid and psychotic episodes, depression with or without suicidal tendencies
, dementia. A common but less serious side effects and 'the
nausea. Less frequent side effects are: irregularities'
cardiac and / or palpitations, orthostatic hypotension, episodes of brad
icinesia (phenomenon "on-off"), anorexia, vomiting, dizziness, drowsiness
. Rarely known gastrointestinal bleeding, peptic du
odenale, hypertension, phlebitis, leucopenia, agranulocytosis and thrombocytosis
open, hemolytic anemia and hemolytic anemia, chest pain, dyspnea, and paresthesia
. Levodopa, levodopa + carbidopa, levodopa + benserazide can 'pr
ovoce drowsiness and and very rarely 'been associated with excessive daytime nnolenza know
and episodes of sudden sleep onset. Also ALTR
the side effects described with levodopa are: psychiatric
matrix (euphoria, confusion, insomnia, delirium, nightmares, hallucinations and delusions
, agitation and anxiety), neurological (ataxia, fainting,
ument to hand tremor, insensitivity ', muscle cramps, trismus,
activation of latent Horner's syndrome), gastrointestinal (st
ipsi, diarrhea, and abdominal pain, bloating, hiccups, s
cialorrea, bitter mouth, dry mouth, burning sensation
tongue, dysphagia, bruxism) dermatological (flushing, increased sweating
, hair loss, rash, dark sweat), urogen
itali (urinary retention, incontinence, dark urine, priapism), org ani
sense (blurred vision, diplopia, dilated pupils, ocular crisis
logire), metabolic (loss or weight gain, edema), others (zza
weakness, fatigue ', headache, hoarseness, malaise, hot flashes,
sense of excitement, irregular breathing pattern, policy
syndrome neuroleptic malignant melanoma malignant), abnormal laboratory test (
increases in SGOT, SGPT, LDH, bilirubin, alkaline fatasi
of fos, as well as' increases in blood urea, creatinine, of
'uric acid and positivity' Coombs). Hemolytic anemia and 'exhausted and
rare. In patients treated with dopamine agonists, including
the drug for Parkinson's disease, especially at high doses,
ono s syndrome have been reports of pathological gambling, the
ncremento libido and hypersexuality ', usually reversible
with the reduction or discontinuation of treatment.
0 comments:
Post a Comment